Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
Overview of PerkinElmer Inc.
PerkinElmer Inc. is a globally recognized scientific instrumentation and solutions provider that serves the needs of researchers, clinicians, and scientists in diagnostics, life sciences, and applied markets. With decades of expertise, the company combines state-of-the-art technology with deep industry knowledge to deliver instruments and software that empower precise and early insights in analytical and diagnostic processes.
Core Business Areas
PerkinElmer specializes in multiple business areas, including:
- Diagnostics: Offering advanced tools and methodologies designed to support early disease detection and accurate diagnostics.
- Life Sciences: Providing instrumentation and support services that enhance biological research, drug discovery, and genomic studies.
- Food and Applied Markets: Delivering practical solutions tailored to food safety, environmental monitoring, and quality control.
Business Model and Revenue Generation
The company operates by integrating advanced science and technology with customer-focused services, generating revenue through direct sales of high-performance analytical instruments, licensing of proprietary technologies, and ongoing service contracts. The business model emphasizes long-term customer partnerships and continuous innovation, which are vital in meeting the evolving needs of global research communities.
Market Position and Competitive Landscape
Positioned as a significant player in the scientific instrumentation sector, PerkinElmer competes with other global providers by offering an extensive portfolio of integrated solutions. Its competitive edge stems from its deep technical expertise, robust customer service, and strategic investments in research and development. This approach not only addresses current market challenges but also establishes a broad framework that supports complex research endeavors and regulatory needs.
Technological Innovation and Expertise
At its core, PerkinElmer leverages cutting-edge technologies to enable breakthrough discoveries in science and healthcare. The company continuously evolves its product offerings through innovation in instrument design, software integration, and application-specific solutions. These innovations are a direct result of its commitment to deep market insight and technical expertise, ensuring that its customers benefit from the latest advances in scientific research.
Global Reach and Impact
With a presence in numerous countries worldwide, the company functions as a key enabler in global research efforts. By providing technologies that support both clinical and research applications, PerkinElmer contributes significantly to improving healthcare outcomes and advancing scientific understanding. Its global footprint allows it to serve a diverse array of industries, reinforcing its role as a vital partner in enhancing quality of life through scientific progress.
Commitment to Quality and Customer Partnership
PerkinElmer is dedicated to building strategic partnerships with its customers, offering tailored support and service solutions that meet the specific requirements of complex research and diagnostic projects. This commitment is reflected in its holistic approach to customer engagement, combining product excellence with expert consultancy and robust technical assistance.
Conclusion
In summary, PerkinElmer Inc. encapsulates a sophisticated blend of innovation, market insight, and operational excellence. It remains an influential entity in the scientific and healthcare sectors by consistently providing analytical instrumentation and solutions that empower users to achieve early and accurate results. The company’s ability to integrate advanced technology with practical applications makes it an indispensable partner for global research institutions and healthcare providers alike.
PerkinElmer (NYSE: PKI) has announced its participation in the J.P. Morgan Healthcare Conference on January 11, 2021, at 7:30 a.m. ET. CEO Prahlad Singh will present updates on the company’s strategic priorities. The presentation will be accessible via a live audio webcast on PerkinElmer's investor relations website, with a replay available for 90 days post-event. In 2019, PerkinElmer generated approximately $2.9 billion in revenue and operates globally with about 14,000 employees.
PerkinElmer (NYSE: PKI) announced the launch of the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG) by its subsidiary EUROIMMUN, a quantitative test for IgG antibodies against the SARS-CoV-2 S1 antigen. This assay supports vaccine development and may help assess immunity in previously infected individuals. EUROIMMUN aims to file for FDA Emergency Use Authorization (EUA). Production capacity has increased to over three million tests weekly, facilitating significant contributions to global epidemiological studies.
PerkinElmer (NYSE: PKI) will participate in the Wolfe Virtual Healthcare Conference on November 19 at 11:25 a.m. ET. The company's CEO, Prahlad Singh, is set to provide an update on the company's strategic priorities. A live audio webcast can be accessed through the Investors section of PerkinElmer's website, where a replay will also be available for 90 days after the event. PerkinElmer reported approximately $2.9 billion in revenue in 2019, employing about 13,000 people globally.
PerkinElmer, a leader in health innovation, announced its participation in the Stifel Virtual Healthcare Conference on November 17, 2020, at 1:20 p.m. ET. Jamey Mock, SVP and CFO, will discuss the company's strategic priorities and updates. A live audio webcast will be accessible on the company’s Investors webpage, with a replay available for 90 days post-event. In 2019, PerkinElmer reported revenues of approximately $2.9 billion and has a workforce of around 13,000 employees across 190 countries.
PerkinElmer (NYSE: PKI) has announced a recommended all-cash offer to acquire Horizon Discovery Group (LSE: HZD) for approximately $383 million. This acquisition, expected to close in Q1 2021, aims to enhance PerkinElmer's life sciences portfolio with gene editing and gene modulation tools. Horizon, headquartered in the UK, generated $75.5 million in revenue in 2019 and specializes in CRISPR and RNAi technologies. PerkinElmer anticipates the acquisition will modestly boost non-GAAP earnings in the first year and position Horizon favorably in a growing market.
PerkinElmer (NYSE: PKI) announced that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has been cleared for marketing as an in vitro diagnostic device in over 30 countries, complying with the European In Vitro Diagnostic Directive. The test, currently under U.S. FDA review for Emergency Use Authorization, enables detection of SARS-CoV-2, influenza A, influenza B, and RSV from a single sample, crucial for coping with increased testing demands during flu season. The panel is designed to work with PerkinElmer's automated systems for enhanced efficiency in virus detection.
The Board of Directors of PerkinElmer (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, payable on February 12, 2021, to shareholders of record by January 22, 2021. This announcement highlights the company's commitment to returning value to its shareholders.
PerkinElmer reported revenue of approximately $2.9 billion in 2019, employing about 13,000 staff across 190 countries. The company is a key player in the S&P 500 Index.
PerkinElmer, Inc. (NYSE: PKI) projects a 35% increase in reported revenue and a 33% rise in organic revenue for Q3 2020, driven by strong demand for its COVID-19 testing solutions, contributing approximately $280 million to the quarterly revenue. The financial results will be disclosed after market close on October 28, 2020, followed by a conference call hosted by the executive team.
PerkinElmer (NYSE: PKI) announced a partnership with the American Society of Hematology to enhance newborn screening for sickle cell disease (SCD) in sub-Saharan Africa. Approximately 120 million people globally have SCD, with a significant number in Africa, where many children die before age five due to the disease. The collaboration aims to screen 10,000-20,000 newborns annually in participating countries, improving early detection and treatment. This initiative will leverage resources for education, clinical interventions, and advocacy through the Consortium on Newborn Screening in Africa (CONSA).
FAQ
What is the market cap of PERKINELMER (PKI)?
What core markets does PerkinElmer Inc. serve?
How does PerkinElmer generate its revenue?
What distinguishes PerkinElmer from its competitors?
How does PerkinElmer contribute to advancements in healthcare and research?
What is the significance of PerkinElmer's focus on innovation?
In which regions does PerkinElmer operate?
How does PerkinElmer support its customer base?
What industry-specific expertise does PerkinElmer offer?
